Core Viewpoint - China Tongfu (01763) announced a collaboration with Beijing Normal University to sign a patent transfer agreement and a cooperation agreement for the fluorine-18 labeled beta-amyloid imaging agent project, aimed at early diagnosis of Alzheimer's disease [1] Company Summary - The fluorine-18 labeled beta-amyloid imaging agent is a new drug developed by a team led by Professor Cui Mengchao from Beijing Normal University in collaboration with China Tongfu, possessing complete independent intellectual property rights [1] - The drug has shown significant improvement in clinical applications, demonstrating a notable reduction in non-specific uptake in brain white matter compared to similar products approved by the FDA [1] Industry Summary - The signing event marks a significant milestone in the collaboration between academia and industry, emphasizing the importance of transforming scientific research outcomes into national strategic productivity [1] - The nuclear medicine industry is currently experiencing a golden development period, with China Tongfu emerging as a core player in the field due to its deep industry experience and distinctive industrial characteristics [1] - Future collaborations will focus on accelerating the clinical transformation of core results and building a talent cultivation pathway, contributing to the global competition in new nuclear medicine technologies and supporting the high-quality development of China's nuclear medicine sector [1]

Core Viewpoint - The announcement highlights a significant collaboration between China Tongfu (01763) and Beijing Normal University, focusing on the patent transfer and academic-industry cooperation for the development of a new drug, Fluorine [F] Betazone, aimed at early diagnosis of Alzheimer's disease [1] Company Summary - China Tongfu's subsidiary, Atom High-Tech, signed a patent transfer agreement and an academic-industry cooperation agreement with Beijing Normal University on December 10, 2025 [1] - The Fluorine [F] Betazone project is a result of collaboration with Professor Cui Mengchao's team and is characterized by having complete independent intellectual property rights [1] - The drug shows significant improvement in clinical applications, demonstrating a notable reduction in non-specific uptake in brain white matter compared to similar products approved by the FDA [1] Industry Summary - The signing event represents a milestone in the collaboration between academia and industry, aimed at transforming scientific research outcomes into national strategic productivity [1] - The nuclear medicine industry is currently experiencing a golden development period, with Atom High-Tech positioned as a core player due to its deep industry experience and distinctive characteristics [1] - Future collaboration will focus on accelerating the clinical transformation of core results and building a talent cultivation pathway, contributing to global competition in new nuclear medicine technologies and supporting the high-quality development of China's nuclear medicine sector [1]

Core Viewpoint - The announcement highlights a significant collaboration between Yuanzi Gaoke Co., Ltd. and Beijing Normal University, focusing on the development and commercialization of a new drug, Fluorine-18 Betazide, aimed at early diagnosis of Alzheimer's disease [1] Group 1: Collaboration and Agreements - Yuanzi Gaoke signed a patent transfer agreement and a collaborative research agreement with Beijing Normal University on December 10, 2025 [1] - The collaboration is a culmination of previous efforts and marks a critical starting point for transforming scientific research into national productive forces [1] Group 2: Product Development - Fluorine-18 Betazide is a new drug with complete independent intellectual property rights, developed by a team led by Professor Cui Mengchao from Beijing Normal University [1] - The drug has shown significant improvements in clinical applications, particularly in reducing non-specific uptake in brain white matter compared to similar products approved by the FDA [1] Group 3: Industry Context - The nuclear medicine industry is currently experiencing a golden development period, positioning Yuanzi Gaoke as a core player in the field due to its deep industry experience and distinctive characteristics [1] - The partnership aims to accelerate the clinical transformation of core results and build a talent cultivation pathway, contributing to the high-quality development of China's nuclear medicine sector [1]